JP2022529315A5 - - Google Patents

Info

Publication number
JP2022529315A5
JP2022529315A5 JP2021559179A JP2021559179A JP2022529315A5 JP 2022529315 A5 JP2022529315 A5 JP 2022529315A5 JP 2021559179 A JP2021559179 A JP 2021559179A JP 2021559179 A JP2021559179 A JP 2021559179A JP 2022529315 A5 JP2022529315 A5 JP 2022529315A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
alkyl
heteroalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529315A (ja
JP7904691B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000312 external-priority patent/WO2020212760A2/en
Publication of JP2022529315A publication Critical patent/JP2022529315A/ja
Publication of JP2022529315A5 publication Critical patent/JP2022529315A5/ja
Priority to JP2026026596A priority Critical patent/JP2026102607A/ja
Application granted granted Critical
Publication of JP7904691B2 publication Critical patent/JP7904691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559179A 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法 Active JP7904691B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026026596A JP2026102607A (ja) 2019-04-18 2026-02-20 眼障害を処置するための化合物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US62/835,975 2019-04-18
US202062966482P 2020-01-27 2020-01-27
US62/966,482 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026026596A Division JP2026102607A (ja) 2019-04-18 2026-02-20 眼障害を処置するための化合物および方法

Publications (3)

Publication Number Publication Date
JP2022529315A JP2022529315A (ja) 2022-06-21
JP2022529315A5 true JP2022529315A5 (cg-RX-API-DMAC10.html) 2023-04-24
JP7904691B2 JP7904691B2 (ja) 2026-08-13

Family

ID=72837068

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559179A Active JP7904691B2 (ja) 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法
JP2026026596A Pending JP2026102607A (ja) 2019-04-18 2026-02-20 眼障害を処置するための化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026026596A Pending JP2026102607A (ja) 2019-04-18 2026-02-20 眼障害を処置するための化合物および方法

Country Status (9)

Country Link
US (2) US11643429B2 (cg-RX-API-DMAC10.html)
EP (1) EP3955937A4 (cg-RX-API-DMAC10.html)
JP (2) JP7904691B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210154214A (cg-RX-API-DMAC10.html)
CN (1) CN114007625A (cg-RX-API-DMAC10.html)
AU (1) AU2020259997B2 (cg-RX-API-DMAC10.html)
CA (1) CA3136369A1 (cg-RX-API-DMAC10.html)
IL (1) IL287280A (cg-RX-API-DMAC10.html)
WO (1) WO2020212760A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212755A1 (en) 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
CA3196145A1 (en) * 2020-10-21 2022-04-28 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
WO2023067387A2 (en) * 2021-10-20 2023-04-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
US20260109705A1 (en) * 2022-12-20 2026-04-23 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
KR930702369A (ko) * 1990-10-15 1993-09-08 우에노 아키라 에리쓰로마이신 또는 그의 유도체의 2'위치 수식 화합물
WO1995018604A1 (en) * 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
EP1101769A3 (en) * 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
CA2445306C (en) * 2001-04-27 2008-02-12 Pfizer Products Inc. Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
EP1483277A4 (en) * 2002-02-15 2007-10-03 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
GB0310962D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310980D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
PE20090879A1 (es) * 2007-07-30 2009-07-25 Glaxosmithkline Zagreb DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS
JP2012516305A (ja) * 2009-01-30 2012-07-19 グラクソ グループ リミテッド 好中球優位の炎症性疾患の治療のための9−デオキソ−9a−メチル−9a−アザ−9a−ホモエリスロマイシンa誘導体
WO2011100769A2 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
EP2831083A4 (en) * 2012-03-27 2016-03-09 Michael W Burnet INFLAMMATORY MAKROLIDE
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CA3020713A1 (en) 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
US11420995B2 (en) * 2017-03-03 2022-08-23 Synovo Gmbh Anti-infective and anti-inflammatory compounds
CA3057569A1 (en) 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Similar Documents

Publication Publication Date Title
US20170231951A1 (en) Dithiol compounds, derivatives, and uses therefor
JP2022530322A5 (cg-RX-API-DMAC10.html)
CO6310968A2 (es) Derivados de 3,5-diamino sustituido-n-tetrahidropirimidin/imidazolin/diazepam-2-ilidenpirazin-2-carboxamida, utiles como bloqueadores de la actividad del canal de sodio epitelial (enac)
KR20120112537A (ko) 무자극성 안과용 포비돈-요오드 조성물
WO2022146914A1 (en) Cromolyn derivatives and uses thereof
CN101939288A (zh) 用于治疗高眼压的二氟联苯酰胺衍生物
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
JP2024543013A5 (cg-RX-API-DMAC10.html)
KR20220003555A (ko) 안구 장애의 치료를 위한 화합물 및 방법
EP2114398B1 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
JP2024546678A5 (cg-RX-API-DMAC10.html)
ES2261402T3 (es) Derivados de disulfuro utiles para tratar enfermedades alergicas.
JP2023546452A5 (cg-RX-API-DMAC10.html)
JP2004506010A5 (cg-RX-API-DMAC10.html)
ES2222370T3 (es) Derivados de disulfuro de anilina para tratar enfermedades alergicas.
AU2001255675A1 (en) Disulfide derivatives useful for treating allergic diseases
JP2022541311A5 (cg-RX-API-DMAC10.html)
JP2021529189A5 (cg-RX-API-DMAC10.html)
JP2003534317A5 (cg-RX-API-DMAC10.html)
AU2001257227A1 (en) Aniline Disulfide Derivatives for Treating Allergic Diseases
TW202210066A (zh) 對老花眼之治療或預防有用之含硫化合物
JP2006519223A5 (cg-RX-API-DMAC10.html)
JP2021054718A (ja) ドライアイ改善剤
WO2008024765B1 (en) Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
WO2023058673A1 (ja) 老視等の治療または予防に有用な含硫黄化合物